Navigation Links
L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry
Date:5/20/2010

TWINSBURG, Ohio, May 20 /PRNewswire/ -- L.J. Star, Inc., a major supplier of sight glasses, stainless sanitary fittings, and sight flow indicators, announced that it has a suite of solutions for the special demands of process observation in the pharmaceutical and biotech industries.

This product line is used to connect and visually monitor fluid flows, and thereby help maintain strict control of critical processes. The product line was developed over many years of experience with customers at the top 50 pharmaceutical companies and proven in installations around the globe. The line includes sanitary fittings, sight port lighting, cameras, sight indicators, sight glasses, bubble traps, sight glasses, and hygienic clamps.

Pharmaceutical applications require components that come into contact with process fluids not give places for bacteria to hide. For reliable, crevice-free connections, L.J. Star has a full line of precision-made stainless sanitary fittings and hygienic clamps, including clamps with a special safety feature that prevents the clamp from being opened manually if the line is under pressure, as in a steam system.

For these reasons L.J. Star designs use 316 stainless steel materials with electropolished surface finishes that avoid galvanic corrosion and eliminate crevices where harmful bacteria could accumulate. In addition, various products in the line are designed for clean-in-place (CIP) and steam-in-place (SIP) sterilization, which greatly reduce operation costs because process systems do not need to be disassembled for cleaning.

Parenteral applications are those involving the production of injectable drugs, saline, and other solutions. The glass used in sight glasses and sight flow indicators must be of a type that will not leach into the process material. L.J. Star products meet the requirements of USP Type I, making them acceptable for parenteral processes. Many competitor products use soda lime glass, which is not approved for parenteral use by the USP.

The L.J. Star hygienic bubble trap is the first bubble trap made for pharmaceutical applications. It has an electropolish surface and a unique crevice-free self-draining design that allows for CIP and SIP cleaning.

As applicable, these products are tested and certified to various industry standards, which include:

  • Cytotoxicity tests to verify safety in hygienic applications
  • CE and UL recognition
  • DIN 7079 and 7080 quality standards
  • ASME-BPE (bio-processing equipment) specification for the biopharmaceutical industry
  • USP29-661 defining USP Type 1 pharmaceutical use
  • FDA compliance

As part of its rigorous ISO9001-2000 quality control procedure, L.J. Star guarantees it will provide third-party documentation of standards compliance and product performance claims.

To obtain a copy of the L.J. Star Pharmaceutical/Biotech Line Card, call L.J. Star at 330-405-3040, or visit our website at www.ljstar.com/pubs/29.htm.

About L.J. Star

L.J. Star Incorporated provides an extensive line of process observation equipment -- sight glasses, lights, sanitary fittings, and level gage instrumentation. Product lines include Metaglas® Safety Sight Windows, Lumiglas® Explosion Proof Lights and Cameras, Visual Flow Indicators, Sight Ports, Sanitary Clamps, Magnetic Level Gages and Gage Glass. Metaglas is the #1 selling fused sight glass, proven in thousands of installations around the world. Unlike some other sight glasses, it meets stringent DIN 7079 and DIN 7080 quality standards, and it is approved for USP Type I use. For additional information, or to request third-party documentation of standards compliance and product performance claims, contact L.J. Star Incorporated, P.O. Box 1116, Twinsburg, OH 44087. Phone: 330-405-3040. Fax: 330-405-3070. Email: view@ljstar.com. Website: www.ljstar.com.

To download high-resolution image, control-click http://www.ggcomm.com/LJStar/USL.JPG

Media contact: Suzanne Horrigan, 330-405-3040


'/>"/>
SOURCE L.J. Star Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... program for SmartBiome -- a novel metagenomic deep-sequencing research platform. SmartBiome combines ... detection of hundreds of different genes. The selective early access program is ...
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... 6, 2016 According to a new market ... (Polymer, Glass, Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, ... global market is projected to reach USD 8.78 Billion by 2021 ... during the forecast period (2016 to 2021). ... ...
(Date:12/6/2016)... ON (PRWEB) , ... December ... ... or the “Company”), a company focused on discovery and development of precision ... candidates it is developing for Alzheimer’s disease (AD) inhibited the direct neurotoxic ...
Breaking Biology Technology:
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/28/2016)... -- "The biometric system market projected ... biometric system market is in the growth stage and ... The biometric system market is expected to be valued ... of 16.79% between 2016 and 2022. Government initiative in ... smartphones, rising use of biometric technology in financial institutes ...
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
Breaking Biology News(10 mins):